Fibrose cística : avaliação das alterações pulmonares e do sono

• Ano de defesa: 2009
• Autor(a) principal: Silva, Claudia de Castro e
• Tipo de documento: Tese
• Tipo de acesso: Acesso aberto
• Idioma: por
• Palavras-chave em Português: Pneumologia; Fibrose Cística; Melatonina; Estresse Oxidativo
• Link de acesso: http://www.repositorio.ufc.br/handle/riufc/852

Disrupted sleep and nocturnal hypoxia are common in cystic fibrosis (CF). However, the predictors of nocturnal hypoxia in CF are still controversial. In order to identify the risk factors for nocturnal desaturation and sleep disturbances, we carried out a clinical and polysomnographic investigation of CF patients. We studied 30 clinically stable CF cases with clinical lung disease (mean age=12.8; mean forced expiratory volume in 1 second FEV1=65.2), 10 CF cases without significant lung disease (mean age=13.3; mean FEV1=99.8), and 20 controls (mean age=15.5). Patients were evaluated by spirometry, 6-min walk test (6MWT), the Shwachman–Kulczycki (S–K) score, and full overnight polysomnography. Cases with clinical lung disease had lower body mass index, forced vital capacity, and S–K scores. During sleep, five CF cases with clinical lung disease (15%) had SaO2 <90% during more than 30% of total sleep timeand 11 cases (36.6%) had a nadir SaO2 below 85%. FEV1 values for CF cases with clinical lung disease were related to nadir SaO2 (P<0.03) and to mean oxygen saturation SaO2 (P=0.02). A receiver operating characteristic (ROC) analysis determined FEV1 at 64% to be predictive of nocturnal desaturation as defined by minimum SaO2 <85% (sensitivity=92.3%; specificity=77.3%) or SaO2<90% for 30% of sleep time (sensitivity=81.8%; specificity=85.2%). Frequency of impaired sleep was not different in CF cases with (N=5) and without significant lung disease (N=2, P=0.53). Sleep architecture was not significantly different between the two groups. Sleep apnea was present in three CF cases with clinical lung disease and in one case without significant lung disease. In summary, desaturation during sleep can be predicted by FEV1<64%with good sensitivity and specificity. There are no significant differences in sleep architecture between clinically stable CF cases with and without significant lung disease. The recognition of biological markers that can predict clinical deterioration in cystic fibrosis (CF) is a key issue in everyday care of these patients. The (S-K) scores and (FEV1) have been considered the best independent predictors of impairment/disability. The aim of this study was to evaluate the role of high-resolution computed tomography of the chest (HRCT) and the use of the Bhalla score in the detection of functional disability in CF. Cases of both genders, aged older than six years, with CF clinically stable were studied with spirometry, basal oxygen saturation SpO2, the 6MWT, HRCT and the S-K score. Twenty-five patients (15 male, mean age 14.2±5.6) with FEV1 (range 28.6-98.0; mean 62.5±21.8) were studied. Nine patients had severe/moderate respiratory insufficiency (4079). Bronchiectasis was the most frequent finding. Peribronchial thickening, mucus plugging and emphysema, despite being less severe, were also commonly observed. None of the cases presented bullae. Total scores of CT abnormalities varied from 7 to 25 (13.8±4.4). The ROC curve showed the high sensitivity/specificity for Bhalla and S-K scores in the prediction of clinical disability as measured by the FEV1. By comparison, the Bhalla scores showed higher sensitivity than the S-K scores. SpO2 and the 6MWT were not good predictors of disability as measured by functional pulmonary tests. Melatonin, a natural hormone secreted by the pineal gland, has an important function in the synchronization of circadian rhythms, including the sleep–wake cycle, and has been shown to possess significant anti-oxidant properties. To evaluate the effects of exogenous melatonin on sleep and inflammation and oxidative stress markers in CF we conducted a randomized double-blind placebo controlled study initially involving 20 patients with CF. One case failed to conclude the study. All subjects were clinically stable when studied and without recent infectious exacerbation or hospitalization in the last 30 days. Groups were randomized for placebo (N= 10; mean age 12.10±6.0) or melatonin 3.0 mg (N=9; mean age 16.62±8.26) during 21 days. Actigraphy was performed during 6 days before start of medication and in the third week (days 14 to 20) of treatment. Isoprostane and nitrite levels were determined in exhaled breath condensate (EBC) at baseline (day 0) and after treatment (Day 21). Melatonin improved sleep efficiency (p=0.01) and tended to improve sleep latency (p= 0.08). Melatonin reduced EBC nitrite (p=0.01) but not isoprostane. In summary, melatonin administration reduces nitrite levels in EBC and improves sleep measures in clinically stable CF patients.